Ownership Submission
FORM 4
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
Garden State Life Sciences Venture Fund L P
  2. Issuer Name and Ticker or Trading Symbol
AMICUS THERAPEUTICS INC [FOLD]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director __X__ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
(Last)
(First)
(Middle)
C/O QUAKER BIOVENTURES, 2929 ARCH STREET, CIRA CENTRE
3. Date of Earliest Transaction (Month/Day/Year)
06/05/2007
(Street)

PHILADELPHIA, PA 19104
4. If Amendment, Date Original Filed(Month/Day/Year)
6. Individual or Joint/Group Filing(Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I)
(Instr. 4)
7. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/05/2007   C   1,064,822 A (1) 1,064,822 I By Quaker BioVentures, L.P. (2)
Common Stock 06/05/2007   C   354,940 A (1) 1,419,762 D  

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4, and 5)
6. Date Exercisable and Expiration Date
(Month/Day/Year)
7. Title and Amount of Underlying Securities
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 4)
10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 4)
11. Nature of Indirect Beneficial Ownership
(Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Series C Convertible Preferred Stock (1) 06/05/2007   C     396,825 08/16/2005   (1) Common Stock 396,825 $ 0 0 I By Quaker Bioventures, L.P. (2)
Series C Convertible Preferred Stock (1) 06/05/2007   C     132,275 08/16/2005   (1) Common Stock 132,275 $ 0 0 D  
Series C Convertible Preferred Stock (1) 06/05/2007   C     396,825 04/17/2006   (1) Common Stock 396,825 $ 0 0 I By Quaker Bioventures, L.P. (2)
Series C Convertible Preferred Stock (1) 06/05/2007   C     132,275 04/17/2006   (1) Common Stock 132,275 $ 0 0 D  
Series D Convertible Preferred Stock (1) 06/05/2007   C     135,586 09/13/2006   (1) Common Stock 135,586 $ 0 0 I By Quaker Bioventures, L.P. (2)
Series D Convertible Preferred Stock (1) 06/05/2007   C     45,195 09/13/2006   (1) Common Stock 45,195 $ 0 0 D  
Series D Convertible Preferred Stock (1) 06/05/2007   C     135,586 03/09/2007   (1) Common Stock 135,586 $ 0 0 I By Quaker Bioventures, L.P. (2)
Series D Convertible Preferred Stock (1) 06/05/2007   C     45,195 03/09/2007   (1) Common Stock 45,195 $ 0 0 D  

Reporting Owners

Reporting Owner Name / Address Relationships
 Director  10% Owner  Officer  Other
Garden State Life Sciences Venture Fund L P
C/O QUAKER BIOVENTURES
2929 ARCH STREET, CIRA CENTRE
PHILADELPHIA, PA 19104
    X    

Signatures

 Garden State Life Sciences Venture Fund, L.P., By: Quaker BioVentures Capital, L.P., its General Partner, By: Quaker BioVentures Capital LLC, its General Partner, By: /s/ Richard S. Kollender   06/06/2007
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Each of the Series C Convertible Preferred Stock and Series D Convertible Preferred Stock automatically converted into Amicus Therapeutics, Inc. common stock on a one for one basis upon the closing of Amicus Therapeutics, Inc's initial public offering on June 5, 2007.
(2) These shares are owned by Quaker BioVentures, L.P., which is under common control with Garden State Life Sciences Venture Fund L.P. Quaker BioVentures Capital, L.P. serves as the general partner of Quaker BioVentures, L.P. and Garden State Life Sciences Venture Fund L.P. and is the indirect beneficial owner of these shares. Quaker Bioventures Capital LLC serves as the general partner of Quaker Bioventures Capital, L.P. and is also an indirect beneficial owner of these shares. Garden State Life Sciences Venture Fund L.P. disclaims beneficial ownership of these shares except to the extent of its proportionate pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the shares for purposes of section 16 of for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.